Low volume accurate injector

Information

  • Patent Grant
  • 9452261
  • Patent Number
    9,452,261
  • Date Filed
    Sunday, May 8, 2011
    13 years ago
  • Date Issued
    Tuesday, September 27, 2016
    8 years ago
Abstract
Substance-administration apparatus (20) is provided, including a housing (22), and a needle (80), couplable to the housing (22), having a skin-insertion portion 0.3-2.5 mm in length and an outer diameter less than 0.23 mm. A dosage regulator (60) regulates a dosage of substance injected in a single injection through the needle (80). Dosage is selectable by a setting of the dosage regulator (60) as one of a plurality of selectable dosages. At least one dosage is less than or equal to 10 ul. An injection driver (54), activatable by a user, drives the substance through the needle (80). A motor coupled to the injection driver (54) is actuated by the dosage regulator (60) in a pulsatile manner to produce brief periods of high pressure in the apparatus (20) that expel a predetermined volume of the substance through the needle (80) at a controlled rate. Other applications are also described.
Description
FIELD OF THE INVENTION

Applications of the present invention relate generally to substance administration, and specifically to apparatus and methods for administering cosmeceuticals and other drugs.


BACKGROUND OF THE INVENTION

Mesotherapy is described by Wikipedia as a non-surgical cosmetic medicine treatment. Mesotherapy employs multiple injections of pharmaceutical and homeopathic medications, plant extracts, vitamins, and other ingredients into the subcutaneous fat.


WO 08/057976 to Sibbitt et al. describes multiple dose syringe apparatus and methods which are described as being suitable for use to administer multiple small doses of drugs particularly for dermatology, plastic surgery, cosmetic surgery, and neurological medicine. The multiple dose syringes can be constructed from a conventional syringe and conventional plunger with adapters, and also by individual injection mounding.


WO 06/102676 to Perez et al. describes injectable implants that are described as being useful in supplementing soft tissue, particularly skin. The publication relates to dermal filler compositions of biocompatible polyethylene oxides that may be introduced, perhaps by injection, into areas of soft tissue often considered in need of augmentation. Examples include cosmetic enhancement or correction of facial defects due to scarring, aging and the like.


U.S. Pat. No. 3,794,028 to Mueller et al. describes a method of depilation in a human by injecting a dose of chemical depilatory solution into a hair follicle to permanently destroy hair growth at that location. Injection of the chemical depilatory solution may be effected by means of a hypodermic syringe for penetrating beneath the skin surface and for dispensing effective dosage amounts of the depilatory solution into the follicle.


U.S. Pat. No. 5,366,498 to Brannan et al. describes a device for correcting fine superficial facial lines, which comprises a syringe fitted with a 31-33 gauge needle and an aqueous suspension of non-crosslinked fibrillar atelopeptide collagen contained within the syringe barrel, the concentration of collagen in the suspension being in the range of 10 to 50 mg/ml, and the suspension exhibiting an extrusion plot in which there is a smooth substantially linear increase in force up to a substantially constant force in the range of 5 to 30 newtons.


U.S. Pat. No. 6,689,118 to Alchas et al. describes a method of performing an intradermal injection using a drug delivery device containing the substance to be injected. A device for practicing the method includes a needle cannula having a forward tip and a limiter portion having a skin engaging surface surrounding the needle cannula. The needle cannula is in fluid communication with the substance and the tip of the needle cannula extends beyond the skin engaging surface a distance equal to approximately 0.5 mm to 3.0 mm. The needle cannula includes a fixed angle of orientation relative to the plane of the skin engaging surface. The skin engaging surface limits penetration of the needle tip into the skin so that the substance can be expelled through the needle tip into the dermis layer. Preferably, the fixed angle of orientation of the needle cannula is generally perpendicular relative to the skin surface, and the skin engaging surface is generally flat.


US Patent Application Publication 2008/0262436 to Olson describes an injection device comprising a tubular elongated main body, a needle shield slidably arranged in said main body, a needle shield link slidably connected to said needle shield, a enclosure containing medicament arranged in said main body, a needle connected to said enclosure, a plunger operatively arranged to said enclosure for ejecting said medicament through said needle and arranged on its upper part with a number of outwardly extending stop members, spring means arranged to said plunger for operating said plunger, a dose activating means, a needle shield spring surrounding the needle shield link. The device is characterised in that said injection device further comprises a first tubular member rotationally and slidably arranged inside said needle shield link, said tubular member comprises a number or ridges and protrusions on both its outer and inner surfaces, said ridges and protrusions on the outer surface of the tubular member co-operate with guide members arranged on the inner surface of said needle shield link, said ridges and protrusions on the inner surface of the tubular member co-operate with the outwardly extending stop members of the plunger that said injection device further comprises a second tubular member arranged inside said housing, arranged and designed with a number of ridges and protrusions on its inner and outer surfaces capable of setting and delivering a certain preset dose.


U.S. Pat. No. 7,364,570 to Gerondale et al. describes a controlled volume injection/aspiration device includes a syringe having a body for containing a medicament, a needle and a piston slidably disposed within the body. A shell is provided for receiving the syringe body and a plunger rack is disposed within the shell. A manually operated control is disposed in an operative relationship with the plunger rack for moving the plunger rack in a stepwise forward direction causing the piston to eject discrete doses of medication from the syringe body through the needle. The manual operated control is also operative for moving the piston in a stepwise reverse direction causing the piston to aspirate fluid into the syringe body through the needle.


The following references may be of interest:


PCT Publication WO 08/072229 to Levin et al.


U.S. Design Pat. D593,677 to Mudd et al.


U.S. Pat. No. 5,858,001 to Tsals et al.


US Patent Application Publication 2008/0021439 to Brittingham et al.


An insulin pen is described by Wikipedia as an insulin injection system for the treatment of diabetes. A pen has a disposable needle, a vial of insulin, and the pen housing. To use a pen, the user screws on a new needle, turns a dial on the end of the pen to the number of units of insulin needed, and inserts the needle into the skin. She then presses a button on the end of the pen to deliver the selected dose, waits until the dose is delivered, and removes the needle.


SUMMARY OF EMBODIMENTS OF THE INVENTION

In some embodiments of the present invention, a hand-held device is provided which comprises a dosage regulator for regulating the dosage and speed of delivery of substances such as drugs, vitamins, amino acids, collagen, Botox™, viscous substances, and/or other substances to a treatment site on skin of a subject. The hand-held device is couplable to or is coupled to a needle which has a skin-insertion portion that is 0.3-2.5 mm in length, and an outer diameter that is less than 0.23 mm. The hand-held device accommodates variously sized cartridges containing various substances. Expulsion of the substances from the cartridge is controlled by the dosage regulator, which is actuated by a user. The electronic dosage regulator actuates the motor in a pulsatile manner so as to produce brief periods of high pressure in the device that expel a predetermined volume of the substance through the needle at a controlled rate. This pulsatile mode of operation of the device is particularly useful for regulating the pressure of a highly viscous substance, such as collagen and Botox™, as it passes through the needle. Because of this regulation in pressure, the device allows the use of small diameter needles, which reduces or eliminates discomfort associated with multiple injections, as are facilitated by the hand-held device.


The dosage is user-selectable by the user, who adjusts a setting of the dosage regulator. The dosage regulator provides a plurality of possible settings of the dosage, including at least one dosage that is less than or equal to 10 ul (microliters), and typically other dosages that are higher than this value. A user-activatable injection driver drives the substance through the needle.


Additionally, the hand-held device accommodates variously sized cartridges containing various substances. An example of such cartridge includes a vial of Botox™ powder which is applied to the hand-held device, and which functions as the cartridge. Once the vial of Botox™ powder is coupled to the device, a small-diameter needle is coupled to the device, and the device facilitates drawing of saline solution through the needle and into the vial in order to suspend the Botox™ powder. As such, the device eliminates a step in the Botox™ procedure of having to suspend the Botox™ powder externally to the delivery system.


There is therefore provided, in accordance with some applications of the present invention, substance-administration apparatus, including:


a housing;


a needle, couplable to the housing, having a skin-insertion portion 0.3-2.5 mm in length and an outer diameter that is less than 0.23 mm;


a dosage regulator coupled to the housing, which regulates a dosage of a substance injected in a single injection through the needle, the dosage being selectable in accordance with a setting of the dosage regulator to be one of a plurality of selectable dosages, the plurality of selectable dosages including at least one dosage that is less than or equal to 10 ul;


an injection driver, activatable by a user to drive the substance through the needle, and


a motor coupled to the injection driver, the motor being actuated by the dosage regulator in a pulsatile manner so as to produce brief periods of high pressure in the apparatus that expel a predetermined volume of the substance through the needle at a controlled rate.


In some applications of the present invention, the skin-insertion portion is 1-2.5 mm in length.


In some applications of the present invention, the apparatus is generally cylindrical.


In some applications of the present invention, the plurality of selectable dosages includes at least one dosage that is greater than 10 ul.


In some applications of the present invention, the plurality of selectable dosages does not include any dosages that are greater than 50 ul.


In some applications of the present invention, the at least one dosage is 5-10 ul.


In some applications of the present invention, the at least one dosage is 1-5 ul.


In some applications of the present invention, the outer diameter of the needle is less than 0.21 mm.


In some applications of the present invention, the outer diameter of the needle is between 0.15 mm and 0.23 mm.


In some applications of the present invention, the substance includes a viscous substance, and the dosage regulator is configured to regulate the dosage of the viscous substance injected in the single injection through the needle.


In some applications of the present invention, the apparatus includes a cartridge, pre-filled with the substance, couplable to the housing, for providing the substance in a plurality of injections.


In some applications of the present invention, the needle is couplable to the housing by being couplable to the cartridge, and the needle and the cartridge are couplable to the housing by the user, prior to use of the apparatus.


In some applications of the present invention, the cartridge is pre-filled with powder of botulinum toxin, and the housing is configured to receive the cartridge and to facilitate suspension of the powder subsequently to the receiving of the cartridge.


In some applications of the present invention, the apparatus includes the substance, and the substance includes a depilatory agent.


There is additionally provided, in accordance with some applications of the present invention, a substance-administration method, including:


regulating a dosage of a substance by selecting one of a plurality of selectable dosages, the plurality of selectable dosages including at least one dosage that is less than or equal to 10 ul;


inserting a needle having an outer diameter that is less than 0.23 mm into skin of a subject to a depth of 0.3-2.5 mm;


expelling a predetermined volume of the substance through the needle at a controlled rate by producing brief periods of high pressure in a device used to administer the substance; and


administering the substance at the selected dosage through the needle.


In some applications of the present invention, inserting the needle includes inserting the needle to a depth of 1-2.5 mm.


In some applications of the present invention, the plurality of selectable dosages further includes at least one dosage that is greater than 10 ul, and selecting includes selecting the at least one dosage that is greater than 10 ul.


In some applications of the present invention, the plurality of selectable dosages does not include any dosages that are greater than 50 ul, and selecting includes selecting a dosage from the plurality of selectable dosages that does not include any dosages that are greater than 50 ul.


In some applications of the present invention, the at least one dosage is 5-10 ul, and selecting includes selecting the at least one dosage that is 5-10 ul.


In some applications of the present invention, the at least one dosage is 1-5 ul, and selecting includes selecting the at least one dosage that is 1-5 ul.


In some applications of the present invention, the outer diameter of the needle is less than 0.21 mm, and inserting the needle includes inserting the needle that has an outer diameter that is less than 0.21 mm.


In some applications of the present invention, the substance includes a depilatory agent, and administering the substance includes administering the depilatory agent.


In some applications of the present invention, the substance includes a viscous substance, and administering the substance includes administering the viscous substance.


In some applications of the present invention, the method includes coupling to the needle a cartridge that is pre-filled with the substance, and providing the substance from the cartridge in a plurality of injections.


In some applications of the present invention, the cartridge is pre-filled with powder of botulinum toxin, and the method further includes receive suspending the powder prior to the providing the substance from the cartridge in the plurality of injections.


In some applications of the present invention, inserting the needle in the skin includes inserting the needle in at least one site selected from the group consisting of: skin of a face of the subject and skin of a neck of the subject.


In some applications of the present invention, inserting the needle in the at least one selected site includes inserting the needle and administering the substance at at least 5 sites.


In some applications of the present invention, inserting the needle in the at least one selected site includes inserting the needle at two sites separated by less than 1 mm.


There is also provided, in accordance with some applications of the present invention, a substance-administration method, including:


inserting a needle having an outer diameter that is less than 0.23 mm into skin of a subject to a depth of 0.3-2.5 mm;


expelling a predetermined volume of the substance through the needle at a controlled rate by producing brief periods of high pressure in a device used to administer the substance; and


administering the substance at the selected dosage through the needle.


The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawing, in which:





BRIEF DESCRIPTION OF THE DRAWING


FIG. 1 is a schematic illustration of an exploded view of a hand-held device comprising an electronic dosage regulator and a small needle couplable to the hand-held device, the device being configured for administration of substances to a subject, in accordance with some applications of the present invention;



FIG. 2 is a schematic illustration of a portion of the hand-held device of FIG. 1, in accordance with some applications of the present invention;



FIGS. 3A-B are schematic illustrations of components of the hand-held device of FIG. 1, in accordance with some applications of the present invention;



FIGS. 4A-B are schematic illustrations of loading of a cartridge which is then coupled to the hand-held device of FIG. 1, in accordance with some applications of the present invention;



FIGS. 5A-B and 6 are schematic illustrations of coupling a needle to the cartridge of FIGS. 4A-B, in accordance with some applications of the present invention;



FIGS. 7A-B are schematic illustrations of the loading of the cartridge of FIGS. 4A-B into the hand-held device of FIG. 1;



FIG. 8 is a schematic illustration of preparing the hand-held device for use, in accordance with some applications of the present invention;



FIGS. 9 and 10 are schematic illustrations of the hand-held device of FIG. 1 ready for use, in accordance with some applications of the present invention;



FIG. 11 is a schematic illustration of use of the hand-held device of FIG. 1, in accordance with some applications of the present invention;



FIGS. 12A-B are schematic illustrations of the hand-held device of FIG. 1 following use, in accordance with some applications of the present invention; and



FIG. 13 is a schematic illustration of the loading of the hand-held device of FIG. 1, in accordance with some other applications of the present invention.





DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

Reference is now made to FIG. 1, which is a schematic illustration of apparatus 20 for administering a substance, comprising a hand-held housing 22, a needle 80 couplable to housing 22, and, typically, a cartridge 40, e.g., a vial, designated for containing the substance, in accordance with some applications of the present invention. Needle 80 comprises a very-fine needles which has a skin-insertion portion that has a length of 0.3-2.5 mm (e.g., 1-2.5 mm), and an outer diameter D that is less than 0.23 mm, e.g., less than 0.21 mm. For some embodiments, outer diameter D is between 0.15 mm and 0.23 mm. For example, needle 80 may comprise a 32 or 33 gauge needle, or one or more microneedles. The overall length L of needle 80 is between 0.6 and 5 mm. At least the distal portion of housing 22 is generally cylindrical. An electronic dosage regulator 60 is coupled to housing 22, and regulates a dosage of the substance injected in a single injection through needle 80. The dosage is user selectable by a user, who adjusts a setting of the dosage regulator. The dosage regulator provides a plurality of possible settings of the dosage. The dosage range includes at least one dosage that is less than or equal to 10 ul (microliters), e.g., 1-5 ul or 5-10 ul, but may also include dosages that are higher than this value, e.g., greater than 10 ul. Typically, the plurality of selectable dosages does not include any dosages that are greater than 50 ul. Dosage regulator 60 typically comprises a motor (e.g., a stepper motor or a DC motor) and an electronic panel which displays to the user information relating to the dosage. In such an application, dosage regulator 60 comprises a user interface 58 (e.g., a knob or a button) for the user to set the dosage, volume, and/or the speed of delivery of the dosage. The motor of electronic dosage regulator 60 facilitates pulsatile delivery of the viscous substance within cartridge 40, through needle 80, thereby minimizing pressure through the small needle 80 which would otherwise build up in needle 80 without such pulsatile delivery of the substance through needle 80 by the motor of regulator 60.


Hand-held housing 22 comprises an upper body portion 24a and a lower body portion 24b. Upper and lower body portions 24a and 24b are held together by screws 25. A panel 50 is disposed within housing 22 which comprises a structural component and electronics to transfer signals from user interface 58 and a reset button 56 toward regulator 60 coupled to panel 50. The motor of regulator 60 is coupled to a rotator 63 which is in turn coupled to a gear system 64. Gear system 64 actuates the displacement of an injection driver 54. When the user activates apparatus 20 via an actuation button 29 located at an upper portion 28 of housing 22, dosage regulator 60 activates the motor which activates injection driver 54. Regulator 60 actuates the motor in a pulsatile manner so as to produce brief periods of high pressure in apparatus 20 that expel a predetermined volume of the substance through needle 80 at a controlled rate. Every time the user presses actuation button 29, the motor of dosage regulator 60 runs and expels the substance within cartridge 40 through needle 80 by a predetermined, controlled amount. The user may release button 29 when he or she determines sufficient injection to a given area has been achieved.


Injection driver 54 comprises a flat surface 55 which pushes against a plunger 42 disposed within cartridge 40. An elongate rod is coupled to flat surface 55 and slides within a cylindrical housing 52 coupled to panel 50. A structural component 32 is disposed between panel 50 and upper body portion 24a. Structural component 32 is shaped so as to define a first hole 34 which enables passage therethrough of the rod of driver 54 while restricting proximal passage of flat surface 55 of driver 54. Additionally, structural component 32 is shaped so as to define a second hole 36 which enables rotation of rotator 63.


Typically, the motor of dosage regulator 60 is coupled to driver 54 and regulates (1) the speed of movement of driver 54 and (2) the distance driver 54 moves with each injection in order to control the dosage delivered to the treatment site with each injection. The motor is connected to a rotating indicator 62 which indicates the number of rotations of the motor, as is described hereinbelow.


For some embodiments of the present invention, a pre-filled cartridge 40 is couplable to housing 22 by being fed (e.g., slid) into an opening 10 at a distal end of housing 22 (the end of housing 22 that is closest to the skin of the user during the injection of the substance). Typically, the pre-filled cartridge 40 provides the substance to the user in a plurality of injections, e.g., for administration at at least 5 sites of tissue of a subject being administered the substance. For some embodiments, two injection sites are separated by less than 1 mm.


Alternatively, cartridge 40 is coupled to housing 22 without having been pre-filled with the substance. Prior to use, cartridge 40 is loaded with the substance to be administered, e.g., by drawing proximally injection driver 54, as described hereinbelow.


For some embodiments, prior to use of apparatus 20, cartridge 40 is couplable to needle 80 at a distal end of cartridge 40 (e.g., when needle 80 punctures a septum 43 at a distal end 44 of cartridge 40), and then cartridge 40 and needle 80 are couplable to (e.g., slid into) housing 22 by the user, prior to use of apparatus 20. Needle 80 is typically held in place by a needle-holder 70. A cap 72 covers needle 80 when hand-held housing 22 is not being used. Cap 72 is couplable to needle holder 70. Cartridge 40 slides into concave surface 30 which holds cartridge 40. Cartridge 40 is visible through a window 26 at upper body portion 24a of housing 22. Window 26 enables a user to view the amount of substance that has exited cartridge 40 during use of apparatus.


As appropriate for a given application and administered substance, the dosage range may include at least one dosage that is 5-10 ul and/or at least one dosage that is 1-5 ul.


Injection driver 54 may comprise any user-activatable apparatus (e.g., a plunger, as shown) suitable for initiating and/or driving the movement of a substance through a needle into tissue of the subject.


The substance typically comprises one or more components for esthetic or medical treatment of the skin or near underlying tissue, such as adipose tissue. Apparatus 20 is particularly suitable for providing treatments to the face and neck, where known therapies (e.g., mesotherapy) have not provided satisfactory solutions in terms of dosage accuracy and minimization of pain. In particular, the needles in typical mesotherapy guns range from 30 gauge (0.305 mm outer diameter) to 26 gauge (0.457 mm), and frequently provide per-injection dosages of even as high as 100-200 ul. Mesotherapy guns are additionally generally too heavy and bulky to facilitate easy, accurate placement of the needle at a range of sites on the face or neck in close proximity to each other. The large dosages and large needles used in mesotherapy frequently result in leakage of the administered substance out of the injection site, meaning that control of the administered dosage is suboptimal.


Some applications of the present invention solve the problem of the inability of the prior art to adequately treat the face and neck by providing a device that is, for example, similar in general shape and user interface to an insulin pen, but with a significantly shorter needle than is used in an insulin pen. It is noted that, fundamentally, an insulin pen is designed to facilitate systemic delivery of a drug, and therefore has a long needle length, e.g., 5-12 mm. By contrast, in these embodiments of the present invention, the goal is to treat the upper layers of the skin—typically, within 0.3-2.0 mm of the surface, and therefore these embodiments of the invention utilize a significantly shorter needle, e.g., 0.3-2.5 mm in length.


As appropriate for a given application, the administered substance may comprise one or more of the following:


hyaluronic acid;


one or more vitamins (e.g., C, B10, B8, B9, I, B3 B6, B2, E, A, B12);


one or more minerals (e.g., calcium chloride, potassium chloride, magnesium sulphate, sodium acetate, sodium chloride, sodium dihydrogen phosphate);


one or more nucleic acids (e.g., deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, methylcytosine);


one or more amino acids (e.g., Alainin, Arginine, Asparagine, Aspartic acid, Cystein, Glutamin, glutamic acid, glycine, histine, hydroxyproline, isoleucin, Leucine, Lysine, Methionine, Omithine, Phenylalanine, Prolin, Serine, Taurine, Threonin, Tryptophan, Tyrosine, Valine);


one or more coenzymes (e.g., cocarboxylase, coenzyme A, flavin adenine dinucleotide phosphate, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, uridine triphosphate);


one or more reducing agents (e.g., ascorbic acid, glutathione);


Botox™;


Collagen (cross-linked and not cross-linked);


growth hormone at homeopathic concentrations or greater; and


other hormones at homeopathic concentrations or greater.


In some embodiments, apparatus 20 described hereinabove is used to administer a depilatory agent, such as caustic soda, directly into a hair follicle. Advantageously, the small needle diameter and length provided by these embodiments of the invention (e.g., 32 or 33 gauge, 0.3-2.5 mm in length) allows relatively painless and accurate administration of the depilatory agent.



FIG. 2 shows a view that has been flipped from the view as shown in FIG. 1, in accordance with some applications of the present invention. FIG. 2 shows the assembled state of the inner mechanism which couples dosage regulator 60, rotator 63, and gear assembly 64 to driver 54. Panel 50 is coupled to an actuator 66 which is coupled to indicator 62 and records the number or rotations of indicator 62. Actuator 66 quantifies the number of rotations of indicator 62 and transfers the information to a display, thereby indicating the advancement of driver 54 within cartridge 40. For some applications, actuator provides an audible indication of the advancement of driver 54 within cartridge 40. Panel 50 is coupled and electronically coupled to a second user interface 59, e.g., a switch, which, when enabled by the user, turns on or off apparatus 20. Upper body portion 24a is shown in phantom to indicate the flipped view of apparatus 20 in FIG. 2.


As shown, flat surface 55 of driver 54 is disposed in communication with a proximal end of cartridge 40 and plunger 42 disposed therein. Cartridge 40 is shown coupled to needle holder 70 which is, in turn, coupled to cap 72.



FIG. 3A is identical to FIG. 2, as described hereinabove, with the exception that upper body portion 24a is shown as being coupled to the inner components of apparatus 20, in accordance with some applications of the present invention. FIG. 3A is shown without lower body portion 24b so as to show the inner components of apparatus 20.



FIG. 3B is a schematic illustration of a flipped view to the view shown in FIG. 3A, in accordance with some applications of the present invention. As shown, lower body portion 24b is shown as being coupled to the inner components of apparatus 20. FIG. 3b is shown without upper body portion 24a so as to show the inner components of apparatus 20.



FIGS. 4A-B show a user loading cartridge 40 with a solution 100, e.g., saline, prior to use of the hand-held device of apparatus 20, in accordance with some applications of the present invention. As shown, cartridge 40 contains a concentrated powder 90 (i.e., the substance to be injected into the user or by the user to a receiver of the substance) at a distal end and a plunger 42 disposed proximally to powder 90. As shown in FIG. 4A, the user holds in one hand a syringe 102 full of solution 100, and in the other hand holds cartridge 40. A needle coupled to syringe 102 punctures septum 43 at distal end 44 of cartridge 40 so as to facilitate injection of solution 100 into cartridge 40. As solution 100 is injected into cartridge 40, plunger 42 within cartridge 40 slides proximally, as shown in FIG. 4B, and a suspension 104 of powder 90 of the substance to be injected is created.


For some applications of the present invention, cartridge 40 contains Botox™ powder which is loaded with a solution prior to loading of cartridge into hand-held housing 22 of apparatus 20. That is, for such applications, cartridge 40 contains Botox™ powder 90 and a plunger 42. Cartridge 40 is typically disposable.


Reference is again made to FIGS. 4A-B. It is to be noted that cartridge 40 is shown as being loaded with solution 100 by way of illustration and not limitation, and that the scope of the present invention includes use of cartridges that are already pre-loaded with solution 100, i.e., cartridges that already contain suspension 104 of the substance to be injected.



FIGS. 5A-B and 6 show the coupling of needle 80 to cartridge 40, in accordance with some applications of the present invention. The loaded cartridge 40 with suspension 104 of the substance to be injected is coupled to needle holder 70 holding needle 80. Holder 70 is coupled to cartridge 40 at a distal end 44 of cartridge 40 by being screwed, or otherwise coupled to a distal end of hand-held housing 22. A proximal end of needle 80 punctures septum 43, as shown in the cross-sectional illustration in FIG. 6. As such, needle 80 accesses suspension 104 within cartridge 40.



FIGS. 7A-B show the loading of the pre-loaded, or pre-filled cartridge 40 within hand-held housing 22 of apparatus 20, in accordance with some applications of the present invention. As shown, cartridge 40 slides into opening 10 at the distal end of hand-held housing 22. It is to be noted that (1) needle holder 70 and needle 80 may be coupled to cartridge 40, and (2) cap 72 may be coupled to needle holder 72, at any stage before, during, and after loading of cartridge 40 into hand-held housing 22.



FIG. 8 shows expulsion of any air bubbles 106 within cartridge 40 following the loading of the pre-loaded, or pre-filled cartridge 40 within hand-held housing 22, in accordance with some applications of the present invention. The user removes cap 72 to expose the distal end of needle 80 and, viewing the air bubble 106 through window 26 of hand-held housing 22, activates apparatus 20 (i.e., by pushing on the on actuation button 29, as described hereinabove) to expel air bubble 106 from cartridge 40.



FIGS. 9-11 show apparatus 20 loaded with cartridge 40, coupled to needle 80, and ready for use, in accordance with some applications of the present invention. FIG. 9 shows an isometric view of the hand-held device of apparatus 20, and FIG. 10 shows a cross-sectional illustration of the hand-held device of apparatus 20, as described hereinabove. Prior to use, cap 72 is removed. Subsequently, apparatus 20 is turned on by interface 59 (not shown for clarity of illustration) and is set by interface 58 to one of three settings, as shown in FIG. 11. It is to be noted that any suitable number of settings may be selected by interface 58.


Reference is now made to FIGS. 10 and 11. FIG. 11 shows use of hand-held housing 22 of the hand-held device by a user. Prior to use, driver 54 and flat surface 55 ate disposed in their proximal-most position. During the actuation of apparatus 20, the user pushes on actuation button 29 which activates the motor of electronic dosage regulator 60. Activation of the motor effects rotation of rotator 63 which rotates gear assembly 64 to advance distally driver 54 which enters cartridge 40 at a proximal end thereof and pushes plunger 42 distally. As described hereinabove, the motor functions in a pulsatile manner transferring high burst of pressure to driver 54. In turn, driver 54 pushes plunger 42 to expel controlled amounts of suspension 104 containing the substance to be injected through needle 80. Use of the motor in the pulsatile manner at the proximal end of cartridge 40 reduces pressure at distal end 44 of cartridge 40 and through the very-fine needle 80 as the viscous substance is expelled from cartridge 40 and through needle 80. For some applications of the present invention apparatus 20 comprises a pressure sensor at the proximal end of hand-held housing 22 which measures the pressure of the viscous substances which exit the very-fine needle 80.



FIG. 12A shows apparatus 20 following use, in accordance with some applications of the present invention. As shown, cap 72 is again coupled to needle holder 70 in order to cover needle 80. Following use, plunger 42 is disposed at distal end 44 of cartridge 40 and flat surface 55 of driver 54 is disposed at a distal-most position.



FIG. 12B shows resetting of apparatus 20 following use, in accordance with some applications of the present invention. The user pushes distally reset button 56 located at a proximal end of hand-held housing 22, typically by inserting a pin in an opening at the proximal end of hand-held housing 22. Pushing of reset button 56 pulls proximally driver 54 to its start position. Subsequently, needle holder 70 is decoupled from the distal end of hand-held housing 22, e.g., by being unscrewed therefrom, and the empty cartridge 40 is removed, e.g., by being slid distally through opening 10 of hand-held housing 22. Cartridge 40 is typically disposable.



FIG. 13 is a schematic illustration of apparatus 22 prior to use in which a cartridge 40 containing powder 90 is disposed within hand-held housing 22, in accordance with some applications of the present invention. Following the coupling of cartridge 40 (i.e., by sliding cartridge 40 through opening 10 in hand-held housing 22, as described hereinabove), and following the coupling of needle 80 to cartridge 50 via needle holder 70, cartridge is then loaded with a solution in order to suspend powder 90. In such an embodiment, prior to use of apparatus 20, flat surface 55 driver 54 is reversibly coupled to plunger 42 of cartridge 40, e.g., by being magnetically coupled to plunger 42. That is, for such applications of the present invention, flat surface 55 is not disposed in its proximal-most position as described hereinabove.


As such, apparatus 20 eliminates a step in the Botox™ procedure of having to suspend the Botox™ powder externally to the delivery system.


The user then takes a vial of solution and punctures the vial with needle 80, now coupled to cartridge 40 and thereby to hand-held housing 22. The user activates apparatus 20 such that it functions in a manner reverse to the manner as described hereinabove, so as to move driver 54 proximally (thereby move plunger 42 proximally) in order to draw the solution into cartridge 40 and suspend powder 90 disposed within cartridge 40. Apparatus 20 is then actuated to operate as described hereinabove with reference to FIGS. 10 and 11, so as to expel in a controlled manner and with reduced pressure the suspension of powder 90 through needle 80 and inject the substance into the receiver of the substance. For some applications, powder 90 comprises Botox™ powder by way of illustration and not limitation. It is to be noted that powder 90 may comprise powder of any of the designated-for-injection substances listed herein.


For some applications, techniques described herein are practiced in combination with techniques described in one or more of the references cited in the Background section and Cross-references section of the present patent application.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. A substance-administration apparatus, comprising: a housing;a needle, couplable to the housing, having a skin-insertion portion 0.3-2.5 mm in length and an outer diameter that is less than 0.23 mm;a dosage regulator coupled to the housing, which regulates a dosage of a substance expelled in a single injection through the needle, a single dosage from a plurality of selectable dosages being selectable by a user, the plurality of selectable dosages including at least one dosage that is less than or equal to 10 ul;an electromechanical motor automatically actuated by the dosage regulator in a pulsatile manner, the motor being drivingly coupled to a rotator, which rotates about a central axis thereof;an injection driver for driving the substance through the needle, the injection driver having a rotatable gear system drivingly coupled to the rotator;wherein actuation of the motor in the pulsatile manner rotates the rotator and the coupled gear system in the pulsatile manner, to, in turn, drive the injection driver in the pulsatile manner to automatically produce a series of bursts of pressure in the housing that expel the single selected dosage of the substance through the needle at a controlled rate.
  • 2. The apparatus according to claim 1, wherein the skin-insertion portion is 1-2.5 mm in length.
  • 3. The apparatus according to claim 1, wherein the apparatus is generally cylindrical.
  • 4. The apparatus according to claim 1, wherein the plurality of selectable dosages includes at least one dosage that is greater than 10 ul.
  • 5. The apparatus according to claim 1, wherein the plurality of selectable dosages does not include any dosages that are greater than 50 ul.
  • 6. The apparatus according to claim 1, wherein the at least one dosage is 5-10 ul.
  • 7. The apparatus according to claim 1, wherein the at least one dosage is 1-5 ul.
  • 8. The apparatus according to claim 1, wherein the outer diameter of the needle is less than 0.21 mm.
  • 9. The apparatus according to claim 1, wherein the outer diameter of the needle is between 0.15 mm and 0.23 mm.
  • 10. The apparatus according to claim 1, wherein the substance includes a viscous substance, and wherein the dosage regulator is configured to regulate the dosage of the viscous substance injected in the single injection through the needle.
  • 11. The apparatus according to claim 1, wherein the apparatus comprises the substance, and wherein the substance comprises a depilatory agent.
  • 12. The apparatus according to any one of claims 1-11, further comprising a cartridge, pre-filled with the substance, couplable to the housing, for providing the substance in a plurality of injections.
  • 13. The apparatus according to claim 12, wherein the needle is couplable to the housing by being couplable to the cartridge, and wherein the needle and the cartridge are couplable to the housing by the user, prior to use of the apparatus.
  • 14. The apparatus according to claim 12, wherein the cartridge is pre-filled with powder of botulinum toxin, and the injection driver is movable in a reverse direction to draw solution into the cartridge and facilitate suspension of the powder after receipt of the cartridge in the housing.
  • 15. A substance-administration method, comprising: selecting a single dosage of a substance by selecting one of a plurality of selectable dosages from a substance-administration apparatus comprising: a housing, a needle couplable to the housing, a dosage regulator coupled to the housing which regulates the dosage of the substance from one of the plurality of selectable dosages including at least one dosage that is less than or equal to 10 ul, an electromechanical motor automatically actuated by the dosage regulator in a pulsatile manner, the motor being drivingly coupled to a rotator, which rotates about a central axis thereof, an injection driver for driving the substance through the needle, the injection driver having a rotatable gear system drivingly coupled to the rotator, wherein actuation of the motor in the pulsatile manner rotates the rotator and the coupled gear system in the pulsatile manner, to, in turn, drive the injection driver in the pulsatile manner to automatically produce a series of bursts of pressure in the housing that expel the single selected dosage of the substance through the needle at a controlled rate;inserting the needle into skin of a subject to a depth of 0.3-2.5 mm, the needle having an outer diameter that is less than 0.23 mm;expelling the single selected dosage of the substance through the needle at a controlled rate by automatically producing the series of bursts of pressure in the device; andadministering the selected dosage of the substance through the needle.
  • 16. The method according to claim 15, wherein inserting the needle comprises inserting the needle to a depth of 1-2.5 mm.
  • 17. The method according to claim 15, wherein the plurality of selectable dosages further includes at least one dosage that is greater than 10 ul, and wherein selecting comprises selecting the at least one dosage that is greater than 10 ul.
  • 18. The method according to claim 15, wherein the plurality of selectable dosages does not include any dosages that are greater than 50 ul, and wherein selecting comprises selecting a dosage from the plurality of selectable dosages that does not include any dosages that are greater than 50 ul.
  • 19. The method according to claim 15, wherein the at least one dosage is 5-10 ul, and wherein selecting comprises selecting the at least one dosage that is 5-10 ul.
  • 20. The method according to claim 15, wherein the at least one dosage is 1-5 ul, and wherein selecting comprises selecting the at least one dosage that is 1-5 ul.
  • 21. The method according to claim 15, wherein the outer diameter of the needle is less than 0.21 mm, and wherein inserting the needle comprises inserting the needle that has an outer diameter that is less than 0.21 mm.
  • 22. The method according to claim 15, wherein the substance includes a depilatory agent, and wherein administering the substance comprises administering the depilatory agent.
  • 23. The method according to claim 15, wherein the substance includes a viscous substance, and wherein administering the substance comprises administering the viscous substance.
  • 24. The method according to any one of claims 15-23, further comprising coupling to the needle a cartridge that is pre-filled with the substance, and providing the substance from the cartridge in a plurality of injections.
  • 25. The method according to claim 24, wherein the cartridge is pre-filled with powder of botulinum toxin, and wherein the method further comprises suspending the powder prior to the providing the substance from the cartridge in the plurality of injections.
  • 26. The method according to any one of claims 15-23, wherein inserting the needle in the skin comprises inserting the needle in at least one site selected from the group consisting of: skin of a face of the subject and skin of a neck of the subject.
  • 27. The method according to claim 26, wherein inserting the needle in the at least one selected site comprises inserting the needle and administering the substance at at least 5 sites.
  • 28. The method according to claim 26, wherein inserting the needle in the at least one selected site comprises inserting the needle at two sites separated by less than 1 mm.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a section 371 of International Application No. PCT/IL2011/000368, filed May 8, 2011, which was published in the English language on Nov. 17, 2011 under International Publication No. WO 2011/141907 which claims the benefit of U.S. Provisional Patent Application No. 61/332,855, filed May 10, 2010, the disclosures of which are incorporated herein by reference. The present application is related to U.S. patent application Ser. No. 12/615,828 to Alon entitled, “Low volume accurate injector,” filed Nov. 10, 2009, which published as US 2010/0145305 and claims the priority of U.S. Provisional Patent Application 61/198,906 to Alon entitled, “Low volume accurate injector,” filed Nov. 10, 2008. All of these applications are incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/IL2011/000368 5/8/2011 WO 00 10/25/2012
Publishing Document Publishing Date Country Kind
WO2011/141907 11/17/2011 WO A
US Referenced Citations (520)
Number Name Date Kind
1795630 Wilson Mar 1931 A
2860635 Wilburn Nov 1958 A
3203269 Perrine Aug 1965 A
3212685 Swan et al. Oct 1965 A
3794028 Mueller Feb 1974 A
3994295 Wulff Nov 1976 A
4195636 Behnke Apr 1980 A
4218724 Kaufman Aug 1980 A
4273122 Whitney et al. Jun 1981 A
4300554 Hessberg et al. Nov 1981 A
4403987 Gottinger Sep 1983 A
4435173 Siposs et al. Mar 1984 A
4465478 Sabelman et al. Aug 1984 A
4565543 Bekkering et al. Jan 1986 A
4585439 Michel Apr 1986 A
4599082 Grimard Jul 1986 A
4601702 Hudson Jul 1986 A
4685903 Cable et al. Aug 1987 A
4698055 Sealfon Oct 1987 A
4810215 Kaneko Mar 1989 A
4850966 Grau et al. Jul 1989 A
4867743 Vaillancourt Sep 1989 A
4886499 Cirelli et al. Dec 1989 A
4919596 Slate et al. Apr 1990 A
4929241 Kulli May 1990 A
4950246 Muller Aug 1990 A
D322671 Szwarc Dec 1991 S
5109850 Blanco et al. May 1992 A
5112317 Michel May 1992 A
5131816 Brown et al. Jul 1992 A
5190521 Hubbard et al. Mar 1993 A
5254096 Rondelet et al. Oct 1993 A
5300045 Plassche, Jr. Apr 1994 A
5342313 Campbell et al. Aug 1994 A
5348544 Sweeney et al. Sep 1994 A
5366498 Brannan et al. Nov 1994 A
5383865 Michel Jan 1995 A
5478315 Brothers et al. Dec 1995 A
5482446 Williamson et al. Jan 1996 A
5496274 Graves et al. Mar 1996 A
5501665 Jhuboo et al. Mar 1996 A
5505709 Funderburk et al. Apr 1996 A
5562686 Sauer et al. Oct 1996 A
5593390 Castellano et al. Jan 1997 A
5616132 Newman Apr 1997 A
5643218 Lynn et al. Jul 1997 A
5645955 Maglica Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5662678 Macklin Sep 1997 A
5672160 Osterlind et al. Sep 1997 A
5690618 Smith Nov 1997 A
D393314 Meisner et al. Apr 1998 S
5766186 Faraz et al. Jun 1998 A
5795675 Maglica Aug 1998 A
5800420 Gross et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5814020 Gross Sep 1998 A
5836920 Robertson Nov 1998 A
5848991 Gross et al. Dec 1998 A
5851197 Marano et al. Dec 1998 A
5858001 Tsals et al. Jan 1999 A
5858008 Capaccio Jan 1999 A
5868710 Battiato et al. Feb 1999 A
5931814 Alex et al. Aug 1999 A
5941850 Shah et al. Aug 1999 A
5948392 Haslwanter et al. Sep 1999 A
5954697 Srisathapat et al. Sep 1999 A
5957895 Sage et al. Sep 1999 A
5968011 Larsen et al. Oct 1999 A
5993423 Choi Nov 1999 A
6004297 Steenfeldt-Jensen et al. Dec 1999 A
6033245 Yamkovoy Mar 2000 A
6033377 Rasmussen et al. Mar 2000 A
6064797 Crittendon et al. May 2000 A
6074369 Sage et al. Jun 2000 A
6186982 Gross et al. Feb 2001 B1
6200289 Hochman et al. Mar 2001 B1
6200296 Dibiasi et al. Mar 2001 B1
6224569 Brimhall May 2001 B1
6248093 Moberg Jun 2001 B1
6277095 Kriesel et al. Aug 2001 B1
6277098 Klitmose et al. Aug 2001 B1
6277099 Strowe et al. Aug 2001 B1
6287283 Ljunggreen et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6302633 Poe Oct 2001 B1
6336729 Pavelle et al. Jan 2002 B1
6345968 Shupe Feb 2002 B1
6377848 Garde et al. Apr 2002 B1
6391005 Lum et al. May 2002 B1
6423029 Elsberry Jul 2002 B1
D465026 May et al. Oct 2002 S
6458102 Mann et al. Oct 2002 B1
6485461 Mason et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6500150 Gross et al. Dec 2002 B1
6503231 Prausnitz et al. Jan 2003 B1
6511336 Turek et al. Jan 2003 B1
6517517 Farrugia et al. Feb 2003 B1
D471274 Diaz et al. Mar 2003 S
D471983 Hippolyte et al. Mar 2003 S
6558351 Steil et al. May 2003 B1
6589229 Connelly et al. Jul 2003 B1
6595956 Gross Jul 2003 B1
6595960 West et al. Jul 2003 B2
6645181 Lavi et al. Nov 2003 B1
6652482 Hochman Nov 2003 B2
6656158 Mahoney et al. Dec 2003 B2
6656159 Flaherty Dec 2003 B2
6659980 Moberg et al. Dec 2003 B2
6673033 Sciulli et al. Jan 2004 B1
6679862 Diaz et al. Jan 2004 B2
6689118 Alchas et al. Feb 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6722916 Buccinna et al. Apr 2004 B2
6743211 Prausnitz et al. Jun 2004 B1
6749587 Flaherty Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6768425 Flaherty et al. Jul 2004 B2
6786890 Preuthun et al. Sep 2004 B2
6800071 McConnell et al. Oct 2004 B1
6805687 Dextradeur et al. Oct 2004 B2
6824529 Gross et al. Nov 2004 B2
6843782 Gross et al. Jan 2005 B2
6854620 Ramey Feb 2005 B2
6905298 Haring Jun 2005 B1
6908452 Diaz et al. Jun 2005 B2
6960192 Flaherty et al. Nov 2005 B1
6997727 Legrady et al. Feb 2006 B1
7001360 Veasey et al. Feb 2006 B2
7034223 Fan et al. Apr 2006 B2
7048715 Diaz et al. May 2006 B2
7060054 Nissels Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7097637 Triplett et al. Aug 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7144384 Gorman et al. Dec 2006 B2
D544092 Lewis Jun 2007 S
7225694 Said Jun 2007 B2
7247149 Beyerlein Jul 2007 B2
7250037 Shermer et al. Jul 2007 B2
7267669 Staunton et al. Sep 2007 B2
7291132 DeRuntz et al. Nov 2007 B2
7291159 Schmelzeisen-Redeker et al. Nov 2007 B2
7303549 Flaherty et al. Dec 2007 B2
7344385 Chen Mar 2008 B2
7364570 Gerondale et al. Apr 2008 B2
7390314 Stutz, Jr. et al. Jun 2008 B2
7407493 Cane′ Aug 2008 B2
D578210 Muta et al. Oct 2008 S
7455663 Bikovsky Nov 2008 B2
7465290 Reilly Dec 2008 B2
7488181 van Haaster Feb 2009 B2
7497842 Diaz et al. Mar 2009 B2
7501587 English Mar 2009 B2
7503786 Kato et al. Mar 2009 B2
7530964 Lavi et al. May 2009 B2
7547281 Hayes et al. Jun 2009 B2
7565208 Harris et al. Jul 2009 B2
7569050 Moberg et al. Aug 2009 B2
D600341 Loerwald Sep 2009 S
7585287 Bresina et al. Sep 2009 B2
7588559 Aravena et al. Sep 2009 B2
7589974 Grady et al. Sep 2009 B2
D602155 Foley et al. Oct 2009 S
D602586 Foley et al. Oct 2009 S
D604835 Conley Nov 2009 S
7628770 Ethelfeld Dec 2009 B2
7628772 McConnell et al. Dec 2009 B2
7628782 Adair et al. Dec 2009 B2
7637891 Wall Dec 2009 B2
7637899 Woolston et al. Dec 2009 B2
7641649 Moberg et al. Jan 2010 B2
7660627 McNichols et al. Feb 2010 B2
7678079 Shermer et al. Mar 2010 B2
7682338 Griffin Mar 2010 B2
7686787 Moberg et al. Mar 2010 B2
7699829 Harris et al. Apr 2010 B2
7699833 Moberg et al. Apr 2010 B2
7704088 Sakamoto Apr 2010 B2
7704227 Moberg et al. Apr 2010 B2
7704229 Moberg et al. Apr 2010 B2
7704231 Pongpairochana et al. Apr 2010 B2
7708717 Estes et al. May 2010 B2
7713238 Mernoe May 2010 B2
7713240 Istoc et al. May 2010 B2
7717913 Novak et al. May 2010 B2
7722574 Toman et al. May 2010 B2
7736344 Moberg et al. Jun 2010 B2
7744589 Mounce et al. Jun 2010 B2
7749194 Edwards et al. Jul 2010 B2
7776030 Estes et al. Aug 2010 B2
7780637 Jerde et al. Aug 2010 B2
7789857 Moberg et al. Sep 2010 B2
7801599 Young et al. Sep 2010 B2
7806868 De Polo et al. Oct 2010 B2
7828528 Estes et al. Nov 2010 B2
7837659 Bush, Jr. et al. Nov 2010 B2
7846132 Gravesen et al. Dec 2010 B2
7854723 Hwang et al. Dec 2010 B2
7857131 Vedrine Dec 2010 B2
7879025 Jacobson et al. Feb 2011 B2
7918825 O'Connor et al. Apr 2011 B2
7935104 Yodfat et al. May 2011 B2
7935105 Miller et al. May 2011 B2
7938803 Mernoe et al. May 2011 B2
7955305 Moberg et al. Jun 2011 B2
7967784 Pongpairochana et al. Jun 2011 B2
7967795 Cabiri Jun 2011 B1
7981105 Adair et al. Jul 2011 B2
7988683 Adair et al. Aug 2011 B2
7993300 Nyholm et al. Aug 2011 B2
7993301 Boyd et al. Aug 2011 B2
7998111 Moberg et al. Aug 2011 B2
8021357 Tanaka et al. Sep 2011 B2
8025658 Chong et al. Sep 2011 B2
8029469 Ethelfeld Oct 2011 B2
8034019 Nair et al. Oct 2011 B2
8038666 Triplett et al. Oct 2011 B2
8057431 Woehr et al. Nov 2011 B2
8057436 Causey et al. Nov 2011 B2
8062253 Nielsen et al. Nov 2011 B2
8066694 Wagener Nov 2011 B2
D650079 Presta et al. Dec 2011 S
D650903 Kosinski et al. Dec 2011 S
8086306 Katzman et al. Dec 2011 B2
D652503 Cameron et al. Jan 2012 S
8105279 Mernoe et al. Jan 2012 B2
8114046 Covino et al. Feb 2012 B2
8114064 Alferness et al. Feb 2012 B2
8114066 Naef et al. Feb 2012 B2
D657462 Siroky Apr 2012 S
8147446 Yodfat et al. Apr 2012 B2
8152764 Istoc et al. Apr 2012 B2
8152770 Reid Apr 2012 B2
8152779 Cabiri Apr 2012 B2
8152793 Keinanen et al. Apr 2012 B2
8157693 Waksmundzki Apr 2012 B2
8162674 Cho et al. Apr 2012 B2
8162923 Adams et al. Apr 2012 B2
8167841 Teisen-Simony et al. May 2012 B2
8172591 Wertz May 2012 B2
8172804 Bikovsky May 2012 B2
8182462 Istoc et al. May 2012 B2
8197444 Bazargan et al. Jun 2012 B1
8206351 Sugimoto et al. Jun 2012 B2
8221356 Enggaard et al. Jul 2012 B2
8267921 Yodfat et al. Sep 2012 B2
8287520 Drew et al. Oct 2012 B2
8292647 McGrath et al. Oct 2012 B1
8308679 Hanson et al. Nov 2012 B2
8323250 Chong et al. Dec 2012 B2
8372039 Mernoe et al. Feb 2013 B2
8373421 Lindegger et al. Feb 2013 B2
8409142 Causey et al. Apr 2013 B2
8414557 Istoc et al. Apr 2013 B2
8430847 Mernoe et al. Apr 2013 B2
8465455 Cabiri Jun 2013 B2
8469942 Kow et al. Jun 2013 B2
8474332 Bente, IV et al. Jul 2013 B2
8475408 Mernoe et al. Jul 2013 B2
8479595 Vazquez et al. Jul 2013 B2
8495918 Bazargan et al. Jul 2013 B2
8496862 Zelkovich et al. Jul 2013 B2
8512287 Cindrich et al. Aug 2013 B2
8517987 Istoc et al. Aug 2013 B2
8523803 Favreau Sep 2013 B1
8556856 Bazargan et al. Oct 2013 B2
8562364 Lin et al. Oct 2013 B2
8574216 Istoc et al. Nov 2013 B2
8603026 Favreau Dec 2013 B2
8603027 Favreau Dec 2013 B2
8628510 Bazargan et al. Jan 2014 B2
8674288 Hanson et al. Mar 2014 B2
8679060 Mernoe et al. Mar 2014 B2
8690855 Alderete, Jr. et al. Apr 2014 B2
8708961 Field et al. Apr 2014 B2
8751237 Kubota Jun 2014 B2
8753326 Chong et al. Jun 2014 B2
8753331 Murphy Jun 2014 B2
8764707 Moberg et al. Jul 2014 B2
8764723 Chong et al. Jul 2014 B2
8771222 Kanderian, Jr. et al. Jul 2014 B2
8777896 Starkweather et al. Jul 2014 B2
8777924 Kanderian, Jr. et al. Jul 2014 B2
8777925 Patton Jul 2014 B2
8784369 Starkweather et al. Jul 2014 B2
8784370 Lebel et al. Jul 2014 B2
8790295 Sigg et al. Jul 2014 B1
8795224 Starkweather et al. Aug 2014 B2
8795231 Chong et al. Aug 2014 B2
8795260 Drew Aug 2014 B2
8801668 Ali et al. Aug 2014 B2
8801679 Iio et al. Aug 2014 B2
8810394 Kalpin Aug 2014 B2
8814379 Griffiths et al. Aug 2014 B2
9061104 Daniel Jun 2015 B2
9061110 Avery et al. Jun 2015 B2
9089475 Fangrow Jul 2015 B2
9089641 Kavazov Jul 2015 B2
20010025168 Gross et al. Sep 2001 A1
20010041869 Causey et al. Nov 2001 A1
20020010423 Gross et al. Jan 2002 A1
20020029018 Jeffrey Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020055711 Lavi et al. May 2002 A1
20020065488 Suzuki et al. May 2002 A1
20020107487 Preuthun Aug 2002 A1
20020123740 Flaherty et al. Sep 2002 A1
20020161332 Ramey Oct 2002 A1
20020169215 Meng Nov 2002 A1
20030009133 Ramey Jan 2003 A1
20030125671 Aramata et al. Jul 2003 A1
20030135159 Daily et al. Jul 2003 A1
20030160683 Blomquist Aug 2003 A1
20030171717 Farrugia et al. Sep 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040092873 Moberg May 2004 A1
20040116866 Gorman et al. Jun 2004 A1
20040127857 Shemesh et al. Jul 2004 A1
20040158172 Hancock Aug 2004 A1
20040186419 Cho Sep 2004 A1
20040260233 Garibotto et al. Dec 2004 A1
20050033234 Sadowski et al. Feb 2005 A1
20050065466 Vedrine Mar 2005 A1
20050065472 Cindrich et al. Mar 2005 A1
20050071487 Lu et al. Mar 2005 A1
20050113761 Faust et al. May 2005 A1
20050159706 Wilkinson et al. Jul 2005 A1
20050171476 Judson Aug 2005 A1
20050171512 Flaherty Aug 2005 A1
20050177136 Miller Aug 2005 A1
20050197650 Sugimoto et al. Sep 2005 A1
20050203461 Flaherty et al. Sep 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20050283114 Bresina et al. Dec 2005 A1
20060013716 Nason Jan 2006 A1
20060030816 Zubry Feb 2006 A1
20060095014 Ethelfeld May 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173439 Thorne et al. Aug 2006 A1
20060195029 Shults et al. Aug 2006 A1
20060211982 Prestrelski et al. Sep 2006 A1
20060229569 Lavi et al. Oct 2006 A1
20060264889 Moberg et al. Nov 2006 A1
20060264890 Moberg et al. Nov 2006 A1
20060264894 Moberg et al. Nov 2006 A1
20060270987 Peter Nov 2006 A1
20060283465 Nickel et al. Dec 2006 A1
20060293722 Slatkine et al. Dec 2006 A1
20070021733 Hansen et al. Jan 2007 A1
20070049865 Radmer et al. Mar 2007 A1
20070073228 Mernoe et al. Mar 2007 A1
20070118405 Campbell et al. May 2007 A1
20070167912 Causey et al. Jul 2007 A1
20070185449 Mernoe Aug 2007 A1
20070197968 Pongpairochana et al. Aug 2007 A1
20070203454 Shermer et al. Aug 2007 A1
20070233038 Pruitt Oct 2007 A1
20070282269 Carter et al. Dec 2007 A1
20080021439 Brittingham et al. Jan 2008 A1
20080033367 Haury et al. Feb 2008 A1
20080033369 Kohlbrenner et al. Feb 2008 A1
20080033393 Edwards et al. Feb 2008 A1
20080051711 Mounce et al. Feb 2008 A1
20080051730 Bikovsky Feb 2008 A1
20080059133 Edwards et al. Mar 2008 A1
20080097381 Moberg Apr 2008 A1
20080108951 Jerde et al. May 2008 A1
20080140006 Eskuri et al. Jun 2008 A1
20080140018 Enggaard et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080167641 Hansen et al. Jul 2008 A1
20080188813 Miller et al. Aug 2008 A1
20080208138 Lim et al. Aug 2008 A1
20080215006 Thorkild Sep 2008 A1
20080215015 Cindrich et al. Sep 2008 A1
20080243087 Enggaard et al. Oct 2008 A1
20080249473 Rutti et al. Oct 2008 A1
20080262436 Olson Oct 2008 A1
20080269687 Chong et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080274630 Shelton et al. Nov 2008 A1
20080294143 Tanaka et al. Nov 2008 A1
20080306449 Kristensen et al. Dec 2008 A1
20080312601 Cane Dec 2008 A1
20080319416 Yodfat et al. Dec 2008 A1
20090041805 Walker Feb 2009 A1
20090048347 Cohen et al. Feb 2009 A1
20090054750 Jennewine Feb 2009 A1
20090069784 Estes et al. Mar 2009 A1
20090076453 Mejlhede et al. Mar 2009 A1
20090088694 Carter et al. Apr 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090093792 Gross et al. Apr 2009 A1
20090093793 Gross et al. Apr 2009 A1
20090105650 Wiegel et al. Apr 2009 A1
20090124977 Jensen May 2009 A1
20090143730 De Polo et al. Jun 2009 A1
20090143735 De Polo et al. Jun 2009 A1
20090149830 Spector Jun 2009 A1
20090182277 Carter Jul 2009 A1
20090204076 Liversidge Aug 2009 A1
20090209896 Selevan Aug 2009 A1
20090234319 Marksteiner Sep 2009 A1
20090240240 Hines et al. Sep 2009 A1
20090253973 Bashan et al. Oct 2009 A1
20090259176 Yairi Oct 2009 A1
20090281585 Katzman et al. Nov 2009 A1
20090299290 Moberg Dec 2009 A1
20090299397 Ruan et al. Dec 2009 A1
20090326459 Shipway et al. Dec 2009 A1
20090326509 Muse et al. Dec 2009 A1
20100030156 Beebe et al. Feb 2010 A1
20100030198 Beebe et al. Feb 2010 A1
20100049128 McKenzie et al. Feb 2010 A1
20100049144 McConnell et al. Feb 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100076412 Rush et al. Mar 2010 A1
20100094255 Nycz et al. Apr 2010 A1
20100100076 Rush et al. Apr 2010 A1
20100100077 Rush et al. Apr 2010 A1
20100106098 Atterbury Apr 2010 A1
20100121314 Iobbi May 2010 A1
20100137790 Yodfat Jun 2010 A1
20100137831 Tsals Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100145305 Alon Jun 2010 A1
20100162548 Leidig Jul 2010 A1
20100168607 Miesel Jul 2010 A1
20100168683 Cabiri Jul 2010 A1
20100198157 Gyrn et al. Aug 2010 A1
20100204657 Yodfat et al. Aug 2010 A1
20100234767 Sarstedt Sep 2010 A1
20100234830 Straessler et al. Sep 2010 A1
20100241065 Moberg et al. Sep 2010 A1
20100264931 Lindegger et al. Oct 2010 A1
20100274112 Hoss et al. Oct 2010 A1
20100274192 Mernoe Oct 2010 A1
20100280499 Yodfat et al. Nov 2010 A1
20100331826 Field et al. Dec 2010 A1
20110034900 Yodfat et al. Feb 2011 A1
20110054399 Chong et al. Mar 2011 A1
20110054400 Chong et al. Mar 2011 A1
20110066131 Cabiri Mar 2011 A1
20110125056 Merchant May 2011 A1
20110160654 Hanson et al. Jun 2011 A1
20110160666 Hanson et al. Jun 2011 A1
20110160669 Gyrn et al. Jun 2011 A1
20110172645 Moga et al. Jul 2011 A1
20110172745 Na et al. Jul 2011 A1
20110178472 Cabiri Jul 2011 A1
20110201998 Pongpairochana et al. Aug 2011 A1
20110238031 Adair et al. Sep 2011 A1
20110245773 Estes et al. Oct 2011 A1
20110270160 Mernoe Nov 2011 A1
20110282282 Lorenzen et al. Nov 2011 A1
20110282296 Harms et al. Nov 2011 A1
20110295205 Kaufmann et al. Dec 2011 A1
20110313238 Reichenbach et al. Dec 2011 A1
20110319861 Wilk Dec 2011 A1
20110319919 Curry et al. Dec 2011 A1
20120004602 Hanson et al. Jan 2012 A1
20120010594 Holt et al. Jan 2012 A1
20120022344 Kube Jan 2012 A1
20120022499 Anderson et al. Jan 2012 A1
20120029431 Hwang et al. Feb 2012 A1
20120035546 Cabiri Feb 2012 A1
20120041364 Smith Feb 2012 A1
20120041414 Estes et al. Feb 2012 A1
20120071828 Tojo et al. Mar 2012 A1
20120096953 Bente, IV et al. Apr 2012 A1
20120096954 Vazquez et al. Apr 2012 A1
20120101436 Bazargan et al. Apr 2012 A1
20120108933 Liang et al. May 2012 A1
20120129362 Hampo et al. May 2012 A1
20120160033 Kow et al. Jun 2012 A1
20120165733 Bazargan et al. Jun 2012 A1
20120165780 Bazargan et al. Jun 2012 A1
20120226234 Bazargan et al. Sep 2012 A1
20120259282 Alderete, Jr. et al. Oct 2012 A1
20130012875 Gross et al. Jan 2013 A1
20130068319 Plumptre et al. Mar 2013 A1
20130085457 Schiff et al. Apr 2013 A1
20130089992 Yang Apr 2013 A1
20130096509 Avery et al. Apr 2013 A1
20130110049 Cronenberg et al. May 2013 A1
20130133438 Kow et al. May 2013 A1
20130237953 Kow et al. Sep 2013 A1
20130245595 Kow et al. Sep 2013 A1
20130245596 Cabiri et al. Sep 2013 A1
20130253419 Favreau Sep 2013 A1
20130253420 Favreau Sep 2013 A1
20130253421 Favreau Sep 2013 A1
20130296799 Degtiar et al. Nov 2013 A1
20130304021 Cabiri et al. Nov 2013 A1
20130323699 Edwards et al. Dec 2013 A1
20130331791 Gross et al. Dec 2013 A1
20140055073 Favreau Feb 2014 A1
20140055076 Favreau Feb 2014 A1
20140058349 Bazargan et al. Feb 2014 A1
20140083517 Moia et al. Mar 2014 A1
20140094755 Bazargan et al. Apr 2014 A1
20140128807 Moberg et al. May 2014 A1
20140128835 Moberg et al. May 2014 A1
20140135692 Alderete, Jr. et al. May 2014 A1
20140135694 Moberg et al. May 2014 A1
20140142499 Moberg et al. May 2014 A1
20140148784 Anderson et al. May 2014 A1
20140148785 Moberg et al. May 2014 A1
20140163522 Alderete, Jr. et al. Jun 2014 A1
20140194819 Maule et al. Jul 2014 A1
20140194854 Tsals Jul 2014 A1
20140207064 Yavorsky Jul 2014 A1
20140207065 Yavorsky Jul 2014 A1
20140207066 Yavorsky Jul 2014 A1
20140213975 Clemente et al. Jul 2014 A1
20140236087 Alderete, Jr. et al. Aug 2014 A1
20140261758 Wlodarczyk et al. Sep 2014 A1
Foreign Referenced Citations (81)
Number Date Country
1747683 Mar 2006 CN
1863566 Nov 2006 CN
101090749 Dec 2007 CN
201941304 Aug 2011 CN
102186733 Sep 2011 CN
1064693 Sep 1959 DE
0017412 Oct 1980 EP
0222656 May 1987 EP
0401179 Dec 1990 EP
1530979 May 2005 EP
1666080 Jun 2006 EP
2060606 May 2009 EP
2498589 Sep 2012 EP
WO 2009136209 Nov 2009 GB
H07-194701 Aug 1995 JP
H09-505758 Jun 1997 JP
2001-512992 Aug 2001 JP
2002-505601 Feb 2002 JP
2002-507459 Mar 2002 JP
2002-528676 Sep 2002 JP
2003-501157 Jan 2003 JP
2003-527138 Sep 2003 JP
2003-534061 Nov 2003 JP
2004-501721 Jan 2004 JP
2004-512100 Apr 2004 JP
2005-523127 Aug 2005 JP
2005-270629 Oct 2005 JP
2007-509661 Apr 2007 JP
2008-534131 Aug 2008 JP
2008-220961 Sep 2008 JP
2009-502273 Jan 2009 JP
9009202 Aug 1990 WO
9307922 Apr 1993 WO
9407553 Apr 1994 WO
9513838 May 1995 WO
9609083 Mar 1996 WO
9632975 Oct 1996 WO
9700091 Jan 1997 WO
9710012 Mar 1997 WO
9733638 Sep 1997 WO
9857683 Dec 1998 WO
9929151 Jun 1999 WO
9959665 Nov 1999 WO
0025844 May 2000 WO
0187384 Nov 2001 WO
0189607 Nov 2001 WO
0189613 Nov 2001 WO
0202165 Jan 2002 WO
0234315 May 2002 WO
0272182 Sep 2002 WO
03090833 Nov 2003 WO
2004032990 Apr 2004 WO
2004105841 Dec 2004 WO
2005018703 Mar 2005 WO
2005037350 Apr 2005 WO
2006037434 Apr 2006 WO
2006069380 Jun 2006 WO
2006102676 Sep 2006 WO
2006104806 Oct 2006 WO
2007051563 May 2007 WO
2007056504 May 2007 WO
2008001377 Jan 2008 WO
2008014908 Feb 2008 WO
2008057976 May 2008 WO
2008072229 Jun 2008 WO
2008076459 Jun 2008 WO
2008078318 Jul 2008 WO
2009044401 Apr 2009 WO
2009046989 Apr 2009 WO
2009125398 Oct 2009 WO
WO 2009136209 Nov 2009 WO
2009144085 Dec 2009 WO
2010078227 Jul 2010 WO
WO 2010078242 Jul 2010 WO
2011075105 Jun 2011 WO
2011090955 Jul 2011 WO
2011090956 Jul 2011 WO
2011156373 Dec 2011 WO
2012032411 Mar 2012 WO
2012040528 Mar 2012 WO
2012160157 Nov 2012 WO
Non-Patent Literature Citations (100)
Entry
Daikyo Crystal Zenith® polymer, Manufactured by Daikyo Seiko, Ltd.
Copaxone®, Manufactured by Teva Pharmaceutical Industries Ltd.
Int'l Search Report issued May 13, 2009 in Int'l Application No. PCT/IL2008/001312.
Int'l Preliminary Report on Patentability issued Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312; Written Opinion.
Int'l Search Report issued Apr. 26, 2010 in Int'l Application No. PCT/US2009/069552.
Office Action issued Apr. 5, 2010 in U.S. Appl. No. 12/244,666.
Office Action issued Sep. 21, 2010 in U.S. Appl. No. 12/244,666.
Office Action issued Apr. 5, 2010 in U.S. Appl. No. 12/244,688.
Office Action issued Sep. 2, 2010 in U.S. Appl. No. 12/244,688.
Office Action issued Sep. 30, 2010 in U.S. Appl. No. 12/689,250.
Int'l Search Report issued Jan. 12, 2011 in Int'l Application No. PCT/US2010/048556; Written Opinion.
U.S. Appl. No. 60/997,459, filed Oct. 2, 2007.
International Preliminary Report on Patentability issued on Jul. 5, 2011 in International Application No. PCT/US2009/069552; Written Opinion.
Office Action issued Jul. 13, 2011 in U.S. Appl. No. 12/559,563.
Int'l Preliminary Report on Patentability issued Sep. 1, 2011 in Int'l Application No. PCT/US2010/048556.
Office Action issued Sep. 6, 2011 in U.S. Appl. No. 12/345,818.
Office Action issued Feb. 21, 2012 in U.S. Appl. No. 12/689,249.
Int'l Search Report issued Jun. 17, 2011 in Int'l Application No. PCT/US2011/021604.
Int'l Search Report issued Oct. 12, 2011 in Int'l Application No. PCT/US2011/021605.
Office Action issued Oct. 28, 2011 in U.S. Appl. No. 12/615,828.
Int'l Search Report issued Sep. 22, 2011 in Int'l Application No. PCT/IL11/00368; Written Opinion.
U.S. Appl. No. 13/521,181 by Cabiri, filed Jul. 9, 2012.
U.S. Appl. No. 13/521,167 by Cabiri, filed Jul. 9, 2012.
Office Action issued May 16, 2012 in U.S. Appl. No. 12/615,828.
Office Action issued Jul. 2, 2012 in U.S. Appl. No. 13/272,555.
Office Action issued May 3, 2012 in CN Application No. 200880117084.X.
U.S. Appl. No. 13/472,112 by Cabiri, filed May 15, 2012.
U.S. Appl. No. 13/429,840 by Cabiri, filed Mar. 26, 2012.
Int'l Preliminary Report on Patentability issued Aug. 2, 2012 in Int'l Application No. PCT/US2011/021604.
Office Action issued Oct. 9, 2013 in IL Application No. 208634.
Office Action issued Nov. 5, 2013 in JP Application No. 2010-527595.
Office Action issued Sep. 29, 2013 in CN Application No. 201080040968.7.
Office Action issued Nov. 4, 2013 in EP Application No. 11 709 234.6.
U.S. Appl. No. 13/733,516 by Cabiri, filed Jan. 3, 2013.
U.S. Appl. No. 13/873,335 by Filman, filed Apr. 30, 2013.
U.S. Appl. No. 13/892,905 by Cabiri, filed May 13, 2013.
U.S. Appl. No. 13/874,121 by Degtiar, filed Apr. 30, 2013.
U.S. Appl. No. 13/874,085 by Cabiri, filed Apr. 30, 2013.
U.S. Appl. No. 13/874,017 by Cabiri, filed Apr. 30, 2013.
Office Action issued Dec. 17, 2013 in JP Application No. 2012-529808.
Office Action issued Dec. 10, 2013 in CN Application No. 201180006567.4.
Office Action issued Jan. 8, 2014 in U.S. Appl. No. 13/521,167 by Cabiri.
U.S. Appl. No. 29/479,307 by Norton, filed Jan. 14, 2014.
English translation of an Office Action issued Jan. 30, 2013 in CN Application No. 200880117084.X.
U.S. Appl. No. 14/193,692 by Gross, filed Feb. 28, 2014.
Office Action issued Feb. 4, 2014 in EP Application No. 11 707 942.6.
English translation of an Office Action issued Mar. 5, 2014 in CN Application No. 200880117084.X.
Int'l Search Report and Written Opinion issued Apr. 3, 2014 in Int'l Application No. PCT/US2013/078040.
Extended European Search Report issued Mar. 27, 2014 in EP Application No. 14154717.4.
Office Action issued Feb. 28, 2014 in CN Application No. 201180006571.0.
U.S. Appl. No. 14/258,661 by Cabiri, filed Apr. 22, 2014.
Int'l Search Report and Written Opinion issued Jan. 7, 2014 in Int'l Application No. PCT/US2013/065211.
Office Action issued May 23, 2014 in U.S. Appl. No. 13/472,112 by Cabiri.
Office Action issued Jun. 3, 2014 in JP Application No. 2010-527595.
Office Action issued Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross.
Int'l Search Report and Written Opinion issued Jul. 31, 2014 in Int'l Application No. PCT/US2014/033598.
Int'l Search Report and Written Opinion issued Jul. 26, 2013 in Int'l Application No. PCT/US2012/039465.
Int'l Search Report and Written Opinion issued Aug. 5, 2013 in Int'l Application No. PCT/US2013/033118.
U.S. Appl. No. 13/964,651 by Gross, filed Aug. 12, 2013.
Office Action issued Aug. 15, 2013 in CN Application No. 200880117084.X.
Office Action issued Jan. 8, 2013 in JP Application No. 2010-527595.
Int'l Preliminary Report on Patentability issued Feb. 7, 2013 in Int'l Application No. PCT/US2011/021604.
Int'l Preliminary Report on Patentability issued Feb. 7, 2013 in Int'l Application No. PCT/US2011/021605.
Extended European Search Report issued Aug. 7, 2014 in EP Application No. 1417477.4.
Office Action issued Aug. 6, 2014 in EP Application No. 11 707 942.6.
Office Action issued Sep. 2, 2014 in JP Application No. 2012-550069.
Office Action issued Sep. 2, 2014 in JP Application No. 2012-550068.
Office Action issued Aug. 26, 2014 in CN Application No. 201180006567.4.
Int'l Preliminary Report on Patentability issued Oct. 9, 2014 in Int'l Application No. PCT/US2013/033118.
Office Action issued Oct. 9, 2014 in U.S. Appl. No. 13/873,335.
U.S. Appl. No. 14/553,399 by Cabiri, filed Nov. 25, 2014.
Office Action issued Nov. 2, 2014 in CN Application No. 201180006571.0.
Office Action issued Nov. 21, 2014 in U.S. Appl. No. 13/472,112 by Cabiri.
Office Action issued Nov. 21, 2014 in U.S. Appl. No. 13/429,840 by Cabiri.
Int'l Preliminary Report on Patentability issued Nov. 27, 2014 in Int'l Application No. PCT/US2013/039465.
Int'l Preliminary Report on Patentability issued May 14, 2015 in Int'l Application No. PCT/US2013/065211.
Office Action issued May 7, 2015 in JP Application No. 2012-550069.
Office Action issued May 13, 2015 in CN Application No. 201380025566.3.
U.S. Appl. No. 14/715,791 by Cabiri, filed May 19, 2015.
U.S. Appl. No. 14/725,009 by Bar-El, filed May 29, 2015.
Office Action issued May 1, 2015 in U.S. Appl. No. 14/638,525 by Filman.
Office Action issued Jun. 4, 2015 in U.S. Appl. No. 13/667,739 by Cabiri.
U.S. Appl. No. 14/593,051 by Gross, filed Jan. 9, 2015.
Extended European Search Report issued Feb. 23, 2015 in EP Application No. 14166596.8.
Extended European Search Report issued Feb. 23, 2015 in EP Application No. 14166591.9.
Office Action issued Mar. 10, 2015 in CN Application No. 201180006567.4.
Office Action issued Mar. 31, 2015 in JP Application No. 2012-550068.
U.S. Appl. No. 14/683,193 by Cabiri, filed Apr. 10, 2015.
Office Action issued Feb. 20, 2015 in U.S. Appl. No. 13/521,181 by Cabiri.
Office Action issued Feb. 24, 2015 in U.S. Appl. No. 14/258,661 by Cabiri.
U.S. Appl. No. 14/638,525 by Filman, filed Mar. 4, 2015.
Office Action issued Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross.
U.S. Appl. No. 14/850,450 by Gross, filed Sep. 10, 2015.
U.S. Appl. No. 14/861,478 by Cabiri, filed Sep. 22, 2015.
U.S. Appl. No. 14/880,673 by Cabiri, filed Oct. 12, 2015.
Office Action issued Sep. 30, 2015 in U.S. Appl. No. 13/667,739 by Cabiri.
Office Action issued Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri.
Office Action issued Jul. 31, 2015 in U.S. Appl. No. 13/521,181 by Cabiri.
Office Action issued Aug. 13, 2015 in U.S. Appl. No. 14/553,399 by Cabiri.
Notice of Allowance issued Aug. 24, 2015 in U.S. Appl. No. 29/479,307 by Norton.
Related Publications (1)
Number Date Country
20130041346 A1 Feb 2013 US
Provisional Applications (1)
Number Date Country
61332855 May 2010 US